All In Biotech

Drug Trial Radar · NCT00621504

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Ceftriaxone, With Adjunctive Clarithromycin, in the Treatment of Adult Subjects With Community-Acquired Pneumonia

Last checked: Nov 19, 2026Latest source record: Mar 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 606 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

606

Actual

Start

Jan 2008

Primary completion

Dec 2008

Study completion Jun 2009

Sponsor

Lead sponsor
Forest LaboratoriesAbbVie (ABBV)
Sponsor type
Industry
First posted
Feb 22, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of Community-Acquired Pneumonia

Conditions

  • Bacterial Pneumonia

Interventions

  • Ceftaroline fosamil for InjectionDrug

    2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours, for 5 to 7 days

  • IV CeftriaxoneDrug

    1 g dose parenteral infused over 30 minutes, every 24 hours, for 5 to 7 days

  • PlaceboDrug

    Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind

  • ClarithromycinDrug

    In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Cure Rate at Test-of-Cure (TOC) in the Modified Intent-to-Treat Efficacy (MITTE) PopulationsTime frame: 8 to 15 days after last dose of study drug
  2. Clinical Cure Rate for Ceftaroline Compared to That for Ceftriaxone at Test-of-Cure (TOC) in the Clinically Evaluable (CE) PopulationTime frame: 8-15 days after last dose of study drug

Locations

168 sites in 23 countries. Site status is shown where the registry gives one.

  • Investigational site

    Los Angeles, California

  • Investigational Site

    Pasadena, California

  • Investigational Site

    Sacramento, California

  • Investigational Site

    San Diego, California

  • Investigational Site

    Orlando, Florida

  • Investigational Site

    Fort Gordon, Georgia

  • Investigational Site

    Peoria, Illinois

  • Investigational Site

    Baltimore, Maryland

  • Investigational site

    Minneapolis, Minnesota

  • Investigational Site

    Butte, Montana

  • Investigational Site

    Akron, Ohio

  • Investigational Site

    Houston, Texas

  • Investigational Site

    Buenos Aires, Argentina

  • Investigational Site

    Buenos Aires, Argentina

  • Investigational Site

    Buenos Aires, Argentina

  • Investigational Site

    Buenos Aires, Argentina

  • Investigational Site

    Buenos Aires, Argentina

  • Investigational Site

    Buenos Aires, Argentina

  • Investigational Site

    Buenos Aires, Argentina

  • Investigational Site

    Vicente López, Argentina

  • Investigational Site

    Buenos Aires, C.a.b.a., Argentina

  • Investigational Site

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Investigational Site

    Vienna, Austria

  • Investigational Site

    Vienna, Austria

  • Investigational Site 2

    Belo Horizonte, Brazil

  • Investigational Site 1

    Belo Horizonte MG, Brazil

  • Investigational Site

    Campinas, Brazil

  • Investigational Site

    Curitiba-PR, Brazil

  • Investigational Site

    Juiz de Fora, Brazil

  • Investigational site

    Porto Alegre, Brazil

  • Investigational Site

    São Paulo, Brazil

  • Investigational Site

    São Paulo, Brazil

  • Investigational Site

    Goiânia, G.o., Brazil

  • Investigational Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Investigational Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Investigational Site

    São José do Rio Preto, São Paulo, Brazil

  • Investigational Site

    Burgas, Bulgaria

  • Investigational Site

    Sofia, Bulgaria

  • Investigational Site

    Varna, Bulgaria

  • Investigational Site

    Tallinn, Estonia

Showing 40 of 168 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.